(Q33532816)

27 July 2017

title

Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysis (English)

1 reference

cost-effectiveness analysis

27 July 2017

0 references

1 reference

1 reference

8

1 reference

27 July 2017

Jim F Huggett

6

0 references

Graham Rook

object named as

Graham Rook

7

0 references

Keertan Dheda

9

object named as

Keertan Dheda

1 reference

27 July 2017

Robert F Miller

3

1 reference

ORCID Public Data File 2021

Motasim Badri

object named as

Motasim Badri

5

1 reference

ORCID Public Data File 2021

author name string

Anil Pooran

1

1 reference

27 July 2017

Helen Booth

2

1 reference

27 July 2017

Geoff Scott

4

1 reference

27 July 2017

publication date

22 February 2010

1 reference

27 July 2017

published in

BMC Pulmonary Medicine

1 reference

27 July 2017

volume

10

1 reference

27 July 2017

page(s)

7

1 reference

Cost-effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers.

27 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837635

Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837635

Diagnosing tuberculosis infection in the 21st century: new tools to tackle an old enemy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837635

False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837635

An official ATS statement: hepatotoxicity of antituberculosis therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837635

Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837635

Feasibility, acceptability, and cost of tuberculosis testing by whole-blood interferon-gamma assay

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837635

Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837635

Selected RD1 peptides for active tuberculosis diagnosis: comparison of a gamma interferon whole-blood enzyme-linked immunosorbent assay and an enzyme-linked immunospot assay

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837635

Sensitivity of a new commercial enzyme-linked immunospot assay (T SPOT-TB) for diagnosis of tuberculosis in clinical practice

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837635

Enzyme-linked immunospot and tuberculin skin testing to detect latent tuberculosis infection

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837635

Cost-effectiveness of tuberculosis control strategies among immigrants and refugees

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837635

Utility of the antigen-specific interferon-gamma assay for the management of tuberculosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837635

Prospective evaluation of a whole-blood test using Mycobacterium tuberculosis-specific antigens ESAT-6 and CFP-10 for diagnosis of active tuberculosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837635

Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837635

Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837635

Screening for tuberculosis: the port of arrival scheme compared with screening in general practice and the homeless

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837635

Resource implications of patients with multidrug resistant tuberculosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837635

Control and prevention of tuberculosis in the United Kingdom: code of practice 2000. Joint Tuberculosis Committee of the British Thoracic Society

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837635

Isoniazid for preventing tuberculosis in non-HIV infected persons

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837635

Tuberculosis screening of immigrants to low-prevalence countries. A cost-effectiveness analysis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837635

How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837635

Fatal isoniazid-induced hepatitis. Its risk during chemoprophylaxis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837635

Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837635

21 June 2018

The tuberculin skin test

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837635

Anti-tuberculosis medication and the liver: dangers and recommendations in management

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837635

Controlled chemoprophylaxis trials in tuberculosis. A general review

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837635

Toxic hepatitis with isoniazid and rifampin. A meta-analysis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837635

Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research.

21 June 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2466-10-7

Enhanced cost-benefit analysis of strategies for LTBI screening and INH chemoprevention in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2466-10-7

Direct costs of three models for the screening of latent tuberculosis infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2466-10-7

Does the implementation of an interferon-gamma release assay in lieu of a tuberculin skin test increase acceptance of preventive therapy for latent tuberculosis among healthcare workers?

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2466-10-7

Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2466-10-7

Diagnosis of tuberculosis in South African children with a T-cell-based assay: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2466-10-7

Comparison of two commercial interferon-gamma assays for diagnosing Mycobacterium tuberculosis infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2466-10-7

Screening and treatment of latent tuberculosis among healthcare workers at low, moderate, and high risk for tuberculosis exposure: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2466-10-7

Performance of a T-cell-based diagnostic test for tuberculosis infection in HIV-infected individuals is independent of CD4 cell count

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2466-10-7

Interferon-gamma release assays and TB screening in high-income countries: a cost-effectiveness analysis.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837635

Results of a tuberculosis-specific IFN-gamma assay in children at high risk for tuberculosis infection.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2837635

Cost-optimisation of screening for latent tuberculosis in close contacts

31 October 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2466-10-7

The Scope and Impact of Treatment of Latent Tuberculosis Infection in the United States and Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2466-10-7

Should Young Adults with a Positive Tuberculin Test Take Isoniazid?

21 January 2018

1 reference

12 December 2020

Isoniazid for the tuberculin reactor: take it or leave it

1 reference

12 December 2020

Cost-effectiveness of interferon-gamma release assay screening for latent tuberculosis infection treatment in Germany

1 reference

12 December 2020

Cost-effectiveness of interferon-gamma release assay testing for the treatment of latent tuberculosis

1 reference

12 December 2020

Cost-effectiveness of a new interferon-based blood assay, QuantiFERON-TB Gold, in screening tuberculosis contacts

1 reference

12 December 2020

The cost-effectiveness of screening for latent tuberculosis infection

1 reference

12 December 2020

Rapid detection of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells

1 reference

12 December 2020

Direct ex vivo analysis of antigen-specific IFN-gamma-secreting CD4 T cells in Mycobacterium tuberculosis-infected individuals: associations with clinical disease state and effect of treatment

1 reference

12 December 2020

Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2466-10-7

1 reference

Dimensions Publication ID

27 July 2017

0 references

1 reference

27 July 2017

1 reference